Effect of endocrine treatment on voiding and prostate size in men with prostate cancer: A long-term prospective study

Scandinavian Journal of Urology and Nephrology

Volumn 46, Issue 1, 2012, Pages 37-43

  Klarskov, Louise L ^a   Klarskov, Peter ^a,b   Mommsen, Søren ^c,d   Svolgaard, Niels ^e  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c RANDERS REGIONAL HOSPITAL   (Denmark)

^d Middelfart Hospital   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antiandrogens; Endocrine therapy; Local progression; Lower urinary tract symptoms; Prostate cancer; Prostate volume

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; DEATH; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MICTURITION; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LONGITUDINAL STUDIES; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; ORGAN SIZE; PREVALENCE; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL; URINATION; URINATION DISORDERS;

EID: 84856207952     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.3109/00365599.2011.637953     Document Type: Article

References (21)

1. Barkin J, Guimares M, Jacobi G, Pushkar D, Taylor T, van Vierssen Trip OB, on behalf of the SMART-1 Investigator Group. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with dual 5a-reductase inhibitor dutasteride. Eur Urol 2003;44: 461-6.
2. De Reijke TM, Klarskov P. Comparative efficacy of two a1-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. BJU Int 2004;93:757-62.
3. Kaplan SA, Gonzales R, Ogiste J, Te AE. Combination of an a1-blocker, alfuzosin, and a PDE5 inhibitor, sildenafil citrate, is superior to monotherapy in treating lower urinary tract symptoms and sexual dysfunction (abstract). Eur Urol 2006;Suppl 5(2):197.
4. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, et al., for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98.
5. Nordling J. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 2005; 95:1006-12.
6. Roehrborn CG, Siami P, Barkin J, Damiao R, Becher E, Minana B, et al. The Influence of baseline parameters on change in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the combat study. Eur Urol 2009; 55:461-71.
7. Debruyne F, Gres A, Arustamov DL. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008;54:170-80.
8. Bosch JLHR, Griffiths DJ, Blom JHM, Schroeder FH. Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters. J Urol 1989;141:68-72.
9. Caine M, Perlberg S, Gordon R. The treatment of benign prostatic hypertrophy with flutamide (SCH 13521): a placebo-controlled study. J Urol 1975;114:564-8.
10. McConnell JD. Androgen ablation and blockade in the treatment of benign prostatic hyperplasia. Urol Clin N Am 1990;17:661-70.
11. Ostri P, Swartz R, Meyhoff HH. Antiandrogen treatment of benign prostatic hyperplasia: a placebo controlled trial. Urol Res 1988;17:29-33.
12. Bartsch G, McConell JD, Mahler C, Calais da Silva F, Klocker H, Richard F. Endocrine treatment of benign prostatic hyperplasia. In: Chatelain C, Denis L, Foo KT, Khoury S, M.C. Connell J, editors. Benign prostatic hyperplasia. 5th International Consultation on Benign Prostatic Hyperplasia (BPH). Health Publications, Plymbridge Distributors, Plymouth; 2001. p 423-57.
13. Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997;79: 235-46.
14. Iversen P, Johansson J-E, Lodding P, Kylmälä T, Lundmo P, Klarskov P, et al. on behalf of the Scandinavian Prostatic Cancer Group. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1-years. Scand J Urol Nephrol 2006;40:441-52.
15. Mommsen S, Petersen L. Transurethral catheter removal after bilateral orchiectomy for prostatic carcinoma associated with acute urinary retention. Scand J Urol Nephrol 1994;28: 401-4.
16. Varenhorst E, Alund G. Urethral obstruction secondary to carcinoma of the prostate: response to endocrine treatment. Urology 1985;25:354-6.
17. Smith JA, Janknegt RA, Abbou CC, de Gery A. Effect of androgen deprivation therapy on local symptoms and tumour progression in men with metastatic carcinoma of the prostate. Eur Urol 1997;31 Suppl 3:25-9.
18. Klarskov L, Mommsen S, Klarskov P, Svolgaard N. Endocrine treatment and LUTS in men with prostate cancer (abstract). Eur Urol 2006;Suppl 5:250. 42 L. L. Klarskov et al.
19. Andersson L. Design of clinical trials on prostate cancer. Urology 1997;49(Suppl 4A):39-45.
20. Hedlund PO, Damber J-E, Hagerman I, Haukaas S, Henriksson P, Iversen P, et al. and the SPCG-5 Study Group. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2008;42: 220-9.
21. Hansen BJ, Flyger H, Brasso K, Schou J, Nordling J, Thorup Andersen J, et al. Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia. Br J Urol 1995;76: 451-8.